NCT00697346 - Study of MLN8237 in Participants With Advanced Hematological Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 11, 2008

Primary Completion Date

October 1, 2016

Study Completion Date

October 19, 2016

Conditions

B-cell Follicular LymphomaB-cell Marginal Zone LymphomaDiffuse Large B-cell LymphomaB-cell Mantle Cell LymphomaB-cell Small Lymphocytic LymphomaB-Cell Chronic Lymphocytic LeukemiaMultiple MyelomaWaldenstrom's MacroglobulinemiaNoncutaneous Peripheral T-cell Lymphoma Not Otherwise SpecifiedAngioimmunoblastic T-cell LymphomaAnaplastic Large Cell LymphomaEnteropathy Associated T-cell LymphomaNK Lymphoma

Interventions

DRUG

Alisertib

Alisertib (MLN8237) PIC or ECT

Trial Locations (10)

Unknown

Scottsdale

Lexington

Baltimore

Omaha

Hackensack

Buffalo

Chapel Hill

Nashville

Houston

San Antonio